Please assess the completion status of the following clinical trial:

Trial Title: Sugammadex After Continuous Infusion of Rocuronium During Sevoflurane and Propofol Anesthesia (P05949; MK-8616-028)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants at least 20 years but under 65 years of age;~* Participants of American Society of Anesthesiologists (ASA) class 1-3;~* Participants scheduled for a surgical procedure under general anesthesia requiring neuromuscular relaxation with the use of a neuromuscular blocking agent (NMBA) with an anticipated duration of surgery between 2 and 5 hours;~* Participants scheduled for a surgical procedure in supine position;~* Participants who had given written informed consent.~Exclusion Criteria:~* Participants in whom difficult intubation was expected because of anatomical malformations;~* Participants known or suspected to have neuromuscular disorders affecting NMB and/or significant renal dysfunction. In Germany, this also included serum creatinine and blood urea nitrogen outside local reference ranges;~* Participants known or suspected to have a (family) history of malignant hyperthermia;~* Participants known or suspected to have an allergy to medications used during general anesthesia;~* Participants receiving medication interfering with NMBAs, such as antibiotics, anticonvulsants and Mg\^2+; based on the dose and time of administration;~* Pregnant or lactating females;~* Female participants of childbearing potential not using any birth control or using only hormonal contraception as birth control;~* Participants who had already participated in trial CT 19.4.312, or in another trial with sugammadex;~* Participants who had participated in another clinical trial, not pre-approved by Organon, within 30 days of entering into CT 19.4.312.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sugammadex + Sevoflurane (Type: EXPERIMENTAL): After receiving sevoflurane and the last dose of rocuronium, at the reappearance of first twitch (T1; 3-10% starting amplitude), a dose of 4.0 mg/kg sugammadex was administered.
- Sugammadex + Propofol (Type: EXPERIMENTAL): After receiving propofol and the last dose of rocuronium, at the reappearance of first twitch (T1; 3-10% starting amplitude), a dose of 4.0 mg/kg sugammadex was administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).